Stephen Lam Chan

35PUBLICATIONS
145CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Aug 12, 2026
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.

|Jul 29, 2026
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab.

|Mar 26, 2026
Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard-of-Care and Emerging Therapeutic Strategies.

Landon L Chan, Kallista O K Chan, Stephen L Chan

|Mar 02, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study.

Richard S Finn, Masatoshi Kudo, Ivan Borbath

|Feb 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.

Stephen L Chan, Thomas Yau, Robin K Kelley

|Jan 30, 2026
Switching Cancer-associated Venous Thromboembolism Treatment from Continuous LMWH to DOACs: An Evaluation.

Wei Kang, Chin-Yao Shen, Michael Chun-Yuan Cheng

Pageof 6

Frequent Collaborators

6 joint publications

Terry Cheuk-Fung Yip

6 joint publications

John Wong

5 joint publications

Vincent Wai-Sun Wong

5 joint publications

Landon Long Chan